Katy is Co-founder and CEO of Minutia, a U.S. cell therapy start-up working towards the transplant of insulin-producing cells combined with nanosensors to contribute to a functional cure for Type 1 diabetes. A Type 1 diabetic herself, Katy has worked in more than 40 countries creating diagnostic and informational tools at the intersection of technology, health, and underserved communities. Prior to Minutia, Katy spent nearly six years at the Clinton Health Access Initiative (CHAI), where her responsibilities included CHAI’s Global Diabetes program me and various TB/HIV diagnostic device products.